SeekingAlpha · Aug 6, 2026
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsChris ClarkShankar Musunuri - Co-Founder, CEO & ChairmanRita...
OC
NASDAQ · OCGN
Ocugen, Inc.
Healthcare · Biotechnology
$1.37
Down-$0.04 (-2.55%)
Updated Aug 28, 2026, 3:55 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 409.14M
- P/E ratio
- -6.72
- Dividend yield
- 0.00%
- 52-week range
- $1.16 – $2.73
- Volume
- 2.9M
- Avg. volume
- 5.08M
Price performance
OCGN price history
1M range · 21 trading sessions · Daily adjusted prices
OCGN closed at $1.37 after 21 trading sessions, up 8.73% for the selected period.
- Last close
- $1.37
- Period change
- +8.73%
- Period low
- $1.23
- Period high
- $1.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $1.42 | $1.42 | $1.36 | $1.37 | 2.9M |
| Aug 26, 2026 | $1.405 | $1.42 | $1.38 | $1.41 | 2.01M |
| Aug 25, 2026 | $1.39 | $1.43 | $1.38 | $1.40 | 4.59M |
| Aug 24, 2026 | $1.41 | $1.41 | $1.33 | $1.36 | 2.89M |
| Aug 21, 2026 | $1.41 | $1.42 | $1.37 | $1.39 | 2.45M |
| Aug 20, 2026 | $1.45 | $1.46 | $1.38 | $1.39 | 3.96M |
| Aug 19, 2026 | $1.38 | $1.49 | $1.35 | $1.48 | 6.88M |
| Aug 18, 2026 | $1.38 | $1.38 | $1.32 | $1.34 | 2.53M |
| Aug 17, 2026 | $1.34 | $1.38 | $1.32 | $1.375 | 2.5M |
| Aug 14, 2026 | $1.36 | $1.36 | $1.31 | $1.35 | 2.98M |
| Aug 13, 2026 | $1.41 | $1.44 | $1.34 | $1.35 | 3.92M |
| Aug 12, 2026 | $1.37 | $1.42 | $1.365 | $1.40 | 3.18M |
| Aug 11, 2026 | $1.32 | $1.37 | $1.30 | $1.37 | 2.47M |
| Aug 10, 2026 | $1.27 | $1.32 | $1.26 | $1.31 | 3.81M |
| Aug 7, 2026 | $1.26 | $1.30 | $1.25 | $1.28 | 4.54M |
| Aug 6, 2026 | $1.245 | $1.315 | $1.21 | $1.24 | 5.56M |
| Aug 5, 2026 | $1.30 | $1.33 | $1.27 | $1.28 | 6.3M |
| Aug 4, 2026 | $1.275 | $1.325 | $1.24 | $1.31 | 6.55M |
| Aug 3, 2026 | $1.245 | $1.28 | $1.23 | $1.25 | 3.55M |
| Jul 31, 2026 | $1.29 | $1.2986 | $1.23 | $1.23 | 4.15M |
| Jul 30, 2026 | $1.22 | $1.27 | $1.19 | $1.26 | 3.51M |
Latest OCGN news
The latest Smart Investors Daily articles mentioning OCGN.
Stock researchCompany · Overview
OCGN research
Overview
Company profile and research snapshot.
Company profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 27, 2026 | Canaccord Genuity | Buy | — |
| Mar 25, 2026 | Chardan Capital | Buy | — |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Canaccord Genuity | Buy | — |
| Mar 11, 2026 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 6, 2026
Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss
Ocugen (OCGN) Q2 revenue beat but wider EPS loss, stock dips; Phase 3 trials advance.
Benzinga · Aug 6, 2026
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same
Benzinga · Jul 29, 2026
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could accelerate OCU410’s
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
